Ensign Peak Advisors
TPTX

Ensign Peak Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Ensign Peak Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,880
Closed -$292K – 2239
2022
Q1 		$292K Buy
10,880
+2,570
+31% +$86.4K ﹤0.01% 1764
2021
Q4 		$396K Sell
8,310
-7,704
-48% -$344K ﹤0.01% 1712
2021
Q3 		$1.06M Hold
16,014
– – ﹤0.01% 1410
2021
Q2 		$1.25M Hold
16,014
– – ﹤0.01% 1356
2021
Q1 		$1.51M Hold
16,014
– – ﹤0.01% 1244
2020
Q4 		$1.95M Hold
16,014
– – ﹤0.01% 1078
2020
Q3 		$1.4M Buy
16,014
+12,157
+315% +$847K ﹤0.01% 1157
2020
Q2 		$249K Buy
+3,857
New +$223K ﹤0.01% 1562

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ensign Peak Advisors's TPTX Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 10,880 shares — an estimated $292K sold.

Ensign Peak Advisors first reported a position in TPTX in Q2 2020 and held it in 8 quarters. The position peaked at $1.95M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

  • Ensign Peak Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 10,880 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $292K.
  • Ensign Peak Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • Ensign Peak Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.95M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.